City of Hope

Calgent Biotechnology Co., Ltd.

Taipei Medical University

Stembios Technologies, Inc.

Other

National Health Research Institutes

Anp Technologies, Inc.

Fulgent Therapeutics, Inc.

Fulgent Genetics, Inc.

Yen, Yun

Bridgent Biotechnology Inc.

Bluelink Pharmaceuticals, Inc.

Yun Yen

Jing-Ping Liou

James Han Wang

Shiow-Lin Pan

David A Horne

Qiang Liu

Jing Pan

Yate-Ching Yuan

Yubei Zhang

Angela L Perkins Harki

Leila Su

Lufen Chang

Bingsen Zhou

Mou-Shiung Lin

Steve K Chen

Steve S Sommer

Ray Yin

Jang-Yang Chang

James C Oliver

Chien Huang Lin

Bing-Sen Zhou

Kevin Ferreri

Chun-Han Chen

Guihua Sun

Fouad Kandeel

Rasha Shehatta

Jia-Yi Wang

Yun-Ru Liu

James Wang

Thomas Schluep

Mark Davis

John Ryan

The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases

Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Nanoparticles containing a taxane and their use

The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.

Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases

The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.

Compounds and pharmaceutical composition associated with ubiquitination-proteasome system

The invention relates to compounds for inhibiting a cancer cell or a virus. Particularly, the invention provides compounds for inhibiting, treating and/or preventing cancer and Zika virus.

Compounds for inhibiting cancer and virus

The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cancer and liver cancer.

Chlorobenzene substituted azaaryl compounds

The invention relates to a compound of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, multiple myeloma, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Histone deacetylase inhibitors

Provided herein are methods of treating cancer in a subject by administering COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide)). The methods of treating include treating a BRCA1-defective subject, a PARP1 inhibitor-resistant subject or a DNA-damaging anti-cancer agent resistant subject. The methods include treating cancer by administering COH29 and a DNA-damaging anti-cancer agent in a combined synergistic amount.

Treatment of BRCA1-defective cancer or resistant cancers

The present invention provides a method for detecting transplantation failure of a transplanted organ or cells which comprises detecting a donor-positive but recipient-negative DNA marker in the recipient's plasma using pyrophosphorolysis activated polymerization. Because of the high sensitivity, specificity and selectivity of pyrophosphorolysis activated polymerization, transplantation failure can be detected at early stages and treatment can be initiate earlier.

Ultra-high sensitive monitoring of early transplantation failure

Provided herein are methods of treating cancer in a subject, by administering COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide)). The methods of treating include treating a BRCA1-defective subject, a PARP1 inhibitor-resistant subject or a DNA-damaging anti-cancer agent resistant subject. The methods include treating cancer by administering COH29 and a DNA-damaging anti-cancer agent in a combined synergistic amount.

A method of evaluating an action includes (1) obtaining a first stem-cell data related to a subject before performing the action, (2) performing the action on the subject, (3) obtaining a second stem-cell data related to the subject after performing the action, and (4) identifying the effect of the action on the subject based on the first stem-cell data and the second stem-cell data. The subject may be a human or an animal. The action may be taking a drug or taking a nutrient or dietary supplement, which may include fucoidan. Each of the first and second stem-cell data may include the count of a type or types of stem cells and/or the percentage of the type or types of stem cells and may be obtained by the same method including counting cells using a cell counter or cell counting device such as flow cytometer.

Method for increasing number of stem cells in human or animal bodies

Growing community of inventors

Arcadia, CA, United States of America

Yun Yen